Evolent Health announced Q2 2026 results showing revenue of $652.5 million, up from $444.3 million in Q2 2025, with a reduced net loss of $28.4 million. The company raised its full-year 2026 revenue guidance to $2.6-$2.7 billion and expects over 25% revenue growth in 2027, driven by new partnerships and demand for oncology solutions. Despite industry challenges, Evolent projects adjusted EBITDA between $120-$135 million for 2026 and aims to improve cash flow and reduce debt. Upcoming launches include a major Oncology Performance Suite covering 1.5 million lives across 11 states, expected to generate $300 million annually starting December 2026.
MSTR shares surged 16.39% to $153.92 following Bitcoin's rise above $80,000, marking a 48% gain over the past month and leading Nasdaq-100 returns. The company holds 845,050 BTC, bought at an average of $75,412 each, with no recent Bitcoin purchases ...
Social media platform X has filed a lawsuit in UK courts against two named individuals and other unidentified account controllers for allegedly defrauding its creator payment system of at least £207,384. The accused operated a network of cryptocurren...
Ethereum (ETH) has successfully broken above the key $2,560 resistance level and maintained it as support, currently trading near $2,664. Technical indicators like the RSI at 67.16 and a bullish MACD confirm strong upward momentum without being overb...
Craneware PLC has lowered its revenue forecast to around $185 million for the year ending June 2027 following a cyber security incident in July. Despite the setback, the company reported a 7% rise in statutory profit before tax to $25.8 million and a...
Genuine Parts Company (GPC) is rated Buy due to promising growth prospects in its Automotive and Industrial divisions. The company's NAPA independent store network offers significant opportunities for operational improvements, expected to boost North...
